Demir Çaltekin Melike, Caniklioğlu Ayşen
Obstetrics and Gynecology, Yozgat Bozok University, Faculty of Medicine, Yozgat, TUR.
Biochemistry, Yozgat Bozok University, Faculty of Medicine, Yozgat, TUR.
Cureus. 2021 Aug 8;13(8):e17001. doi: 10.7759/cureus.17001. eCollection 2021 Aug.
Objective Delta-like 1 (DLK1) and nesfatin-1 are adipokines that have been shown to affect glucose metabolism. We aimed to search serum DLK1 and nesfatin-1 concentrations at 24-28 weeks of pregnancy in women newly defined with gestational diabetes mellitus (GDM) and investigate the relationship of these adipokines with various metabolic parameters. Methods Serum levels of DLK1 and nesfatin-1 were evaluated in 44 women with GDM, and in 40 healthy pregnant women by enzyme-linked immunosorbent assay (ELISA) kits. While performing oral glucose tolerance test (OGTT) for GDM diagnosis at 24-28 weeks of pregnancy, homeostasis model assessment of insulin resistance (HOMA-IR), lipid profiles, glycosylated hemoglobin (HbA1c) were also measured. Results Maternal serum DLK1 and nesfatin-1 concentrations were found lower in pregnant women with GDM compared with healthy pregnant women (418.4±282.6 vs. 586.7±303 ng/L, p=0.002; 12.2±7.6 vs. 26.7±16.4 ng/ml, p<0.001, respectively). Maternal serum DLK1 levels correlated positively with HOMA-IR and fasting insulin (r=0.395, p=0.008; r=0.374, p=0.012, respectively). Conclusion We determined that DLK1 and nesfatin-1 levels were lower in GDM. Based on this study, it may be considered that DLK1 could be culpable for metabolic disorders in GDM.
Delta样蛋白1（DLK1）和nesfatin-1是已被证明会影响葡萄糖代谢的脂肪因子。我们旨在检测新诊断为妊娠期糖尿病（GDM）的孕妇在妊娠24 - 28周时血清中DLK1和nesfatin-1的浓度，并研究这些脂肪因子与各种代谢参数之间的关系。方法：采用酶联免疫吸附测定（ELISA）试剂盒，对44例GDM孕妇和40例健康孕妇的血清中DLK1和nesfatin-1水平进行评估。在妊娠24 - 28周进行口服葡萄糖耐量试验（OGTT）以诊断GDM时，同时测量胰岛素抵抗稳态模型评估（HOMA-IR）、血脂谱、糖化血红蛋白（HbA1c）。结果：与健康孕妇相比，GDM孕妇的母血清DLK1和nesfatin-1浓度较低（分别为418.4±282.6 vs. 586.7±303 ng/L，p = 0.002；12.2±7.6 vs. 26.7±16.4 ng/ml，p < 0.001）。母血清DLK1水平与HOMA-IR和空腹胰岛素呈正相关（分别为r = 0.395，p = 0.008；r = 0.374，p = 0.01）。结论：我们确定GDM患者的DLK1和nesfatin-1水平较低。基于本研究，可能认为DLK1在GDM的代谢紊乱中起作用。
